ストックスクリーナーアプリを入手
3.37
0.30%
-0.010
Voyager Therapeutics Inc (VYGR) 最新ニュース
Voyager Therapeutics stock hits 52-week low at $3.54 By Investing.com - Investing.com Philippines
Voyager Therapeutics stock hits 52-week low at $3.54 - Investing.com
Voyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025 - Nasdaq
Voyager reveals promising Alzheimer’s therapy data By Investing.com - Investing.com Australia
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - GlobeNewswire
New Alzheimer's Breakthrough: Single-Dose Gene Therapy Slashes Tau Levels by 73% - Stock Titan
Voyager Therapeutics at Virtual CNS Forum: Strategic Insights on Neurotherapeutics - Investing.com UK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc.VYGR - PR Newswire
Voyager Therapeutics' (VYGR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Canaccord Genuity Group Cuts Voyager Therapeutics (NASDAQ:VYGR) Price Target to $12.00 - Armenian Reporter
Voyager Therapeutics (NASDAQ:VYGR) Earns “Buy” Rating from HC Wainwright - Defense World
Voyager Therapeutics COO Robin Swartz sells $30,927 in stock - MSN
Cantor Fitzgerald Reaffirms “Overweight” Rating for Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates - MSN
H.C. Wainwright maintains $30 target on Voyager Therapeutics stock By Investing.com - Investing.com Canada
Voyager Therapeutics’ Earnings Call Highlights Promising Future - TipRanks
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts - Benzinga
Voyager Therapeutics stock hits 52-week low at $3.67 - Investing.com
Voyager Therapeutics stock hits 52-week low at $3.67 By Investing.com - Investing.com Australia
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript - Insider Monkey
Voyager Therapeutics price target lowered to $10 from $12 at Wells Fargo - TipRanks
Voyager Therapeutics Inc earnings missed by $0.22, revenue fell short of estimates - Investing.com
Earnings call transcript: Voyager Therapeutics Q4 2024 sees stock dip post-earnings - Investing.com Australia
Voyager Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Voyager Therapeutics: Strong Financials and Promising Pipeline Drive Buy Rating - TipRanks
Earnings call transcript: Voyager Therapeutics Q4 2024 sees stock dip post-earnings By Investing.com - Investing.com South Africa
Voyager Therapeutics: Q4 Earnings Snapshot - mySA
Voyager Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VOYAGER THERAPEUTICS Earnings Results: $VYGR Reports Quarterly Earnings - Nasdaq
Voyager Therapeutics, Inc. SEC 10-K Report - TradingView
Voyager Therapeutics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - TradingView
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire Inc.
VOYAGER THERAPEUTICS Earnings Preview: Recent $VYGR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rhumbline Advisers Increases Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast - GlobeNewswire
John Stankey Updates Shareholders at Morgan Stanley Technology, Media & Telecom Conference on March 4 - The Globe and Mail
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach - PharmaVoice
When Will Voyager Therapeutics Reveal Its Latest Neurogenetic Medicine Progress? - StockTitan
Voyager Therapeutics (NASDAQ:VYGR) Given “Buy” Rating at HC Wainwright - Defense World
Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment - Marketscreener.com
Voyager Therapeutics Reports Positive Data From Single Ascending Dose Study Of VY7523 - Nasdaq
Voyager Therapeutics Reports Positive Topline Data for VY7523 in Alzheimer’s Disease Trials - Nasdaq
Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease - The Manila Times
Voyager Reports Positive Topline Data for Single Ascending - GlobeNewswire
Can Voyager's Anti-Tau Antibody Break Through in Alzheimer's Treatment? Phase 1 Results Show Promise - StockTitan
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of “Buy” by Brokerages - Defense World
Voyager Therapeutics stock hits 52-week low at $4 - Investing.com India
Voyager Therapeutics stock hits 52-week low at $4 By Investing.com - Investing.com South Africa
3.89%
0.13%
大文字化:
|
ボリューム (24 時間):